BRAFV600E and KIT immunoexpression in early-stage melanoma

BRAFV600E and KIT immunoexpression in early-stage melanoma

Abstract: Melanoma is widely known as the most lethal skin cancer. Specific tumor-related mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease. The current search for biomarkers in early-stage melanomas is a high-priority challenge for physicians and researchers. We aimed to assess the immunoexpression of BRAFV600E and KIT in a case series consisting of 44 early-stage melanomas. Formalin-fixed paraffin-embedded samples were systematically evaluated using a semi-quantitative method based on scores of percentage and intensity for immunostained tumor cells. We observed significant concordance between BRAFV600E and KIT immunoexpression in thin invasive melanomas. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early-stage melanomas.

Saved in:
Bibliographic Details
Main Authors: Germano,Andressa, Cardili,Leonardo, Carapeto,Fernando Cintra Lopes, Landman,Gilles
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Dermatologia 2019
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000400458
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0365-05962019000400458
record_format ojs
spelling oai:scielo:S0365-059620190004004582019-10-11BRAFV600E and KIT immunoexpression in early-stage melanomaGermano,AndressaCardili,LeonardoCarapeto,Fernando Cintra LopesLandman,Gilles Biomarkers, pharmacological Early diagnosis Melanoma Abstract: Melanoma is widely known as the most lethal skin cancer. Specific tumor-related mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease. The current search for biomarkers in early-stage melanomas is a high-priority challenge for physicians and researchers. We aimed to assess the immunoexpression of BRAFV600E and KIT in a case series consisting of 44 early-stage melanomas. Formalin-fixed paraffin-embedded samples were systematically evaluated using a semi-quantitative method based on scores of percentage and intensity for immunostained tumor cells. We observed significant concordance between BRAFV600E and KIT immunoexpression in thin invasive melanomas. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early-stage melanomas.info:eu-repo/semantics/openAccessSociedade Brasileira de DermatologiaAnais Brasileiros de Dermatologia v.94 n.4 20192019-08-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000400458en10.1590/abd1806-4841.20198349
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Germano,Andressa
Cardili,Leonardo
Carapeto,Fernando Cintra Lopes
Landman,Gilles
spellingShingle Germano,Andressa
Cardili,Leonardo
Carapeto,Fernando Cintra Lopes
Landman,Gilles
BRAFV600E and KIT immunoexpression in early-stage melanoma
author_facet Germano,Andressa
Cardili,Leonardo
Carapeto,Fernando Cintra Lopes
Landman,Gilles
author_sort Germano,Andressa
title BRAFV600E and KIT immunoexpression in early-stage melanoma
title_short BRAFV600E and KIT immunoexpression in early-stage melanoma
title_full BRAFV600E and KIT immunoexpression in early-stage melanoma
title_fullStr BRAFV600E and KIT immunoexpression in early-stage melanoma
title_full_unstemmed BRAFV600E and KIT immunoexpression in early-stage melanoma
title_sort brafv600e and kit immunoexpression in early-stage melanoma
description Abstract: Melanoma is widely known as the most lethal skin cancer. Specific tumor-related mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease. The current search for biomarkers in early-stage melanomas is a high-priority challenge for physicians and researchers. We aimed to assess the immunoexpression of BRAFV600E and KIT in a case series consisting of 44 early-stage melanomas. Formalin-fixed paraffin-embedded samples were systematically evaluated using a semi-quantitative method based on scores of percentage and intensity for immunostained tumor cells. We observed significant concordance between BRAFV600E and KIT immunoexpression in thin invasive melanomas. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early-stage melanomas.
publisher Sociedade Brasileira de Dermatologia
publishDate 2019
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000400458
work_keys_str_mv AT germanoandressa brafv600eandkitimmunoexpressioninearlystagemelanoma
AT cardilileonardo brafv600eandkitimmunoexpressioninearlystagemelanoma
AT carapetofernandocintralopes brafv600eandkitimmunoexpressioninearlystagemelanoma
AT landmangilles brafv600eandkitimmunoexpressioninearlystagemelanoma
_version_ 1756412637978034176

Similar Items